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Abstract
One of the most important factors in choosing a treatment strategy for cancer is characterization of biomarkers in cancer
cells. Particularly, recent advances in Monoclonal Antibodies (MAB) as primary-specific drugs targeting tumor receptors
show that their efficacy depends strongly on characterization of tumor biomarkers. Assessment of their status in individual
patients would facilitate selection of an optimal treatment strategy, and the continuous monitoring of those biomarkers and
their binding process to the therapy would provide a means for early evaluation of the efficacy of therapeutic intervention.
In this study we have demonstrated for the first time in live animals that the fluorescence lifetime can be used to detect the
binding of targeted optical probes to the extracellular receptors on tumor cells in vivo. The rationale was that fluorescence
lifetime of a specific probe is sensitive to local environment and/or affinity to other molecules. We attached Near-InfraRed
(NIR) fluorescent probes to Human Epidermal Growth Factor 2 (HER2/neu)-specific Affibody molecules and used our time-
resolved optical system to compare the fluorescence lifetime of the optical probes that were bound and unbound to tumor
cells in live mice. Our results show that the fluorescence lifetime changes in our model system delineate HER2 receptor
bound from the unbound probe in vivo. Thus, this method is useful as a specific marker of the receptor binding process,
which can open a new paradigm in the ‘‘image and treat’’ concept, especially for early evaluation of the efficacy of the
therapy.
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Introduction
One of the most important factors in choosing a proper
treatment strategy for cancer is characterization of biomarkers in
cancer cells, and this can be rather challenging. Particularly,
recent advances in Monoclonal AntiBodies (MAB) as primary-
specific drugs, targeting tumor receptors, show that their efficacy
depends strongly on overexpression of specific receptors.
Furthermore, one of the important factors that is frequently
missing in cancer treatment (mainly using MAB) is continuous
monitoring the response of the tumor receptors to the therapy,
especially at the early stages, to quantify the binding process,
which is critical for evaluation of drug efficacy.
Current standard ex vivo methods, e.g., ImmunoHistoChemistry
(IHC), gene amplification demonstrated by Fluorescent In Situ
Hybridization (FISH), and Enzyme-Linked ImmunoSorbent Assay
(ELISA), are invasive and require biopsies from the patients.
Inherently, biopsies have a risk of missing the malignant lesion
and, during the therapeutic cycle, the number of times that the
biopsy can be taken is limited [1]. Alternative methods currently
under consideration are based on pharmacokinetics of the
radionuclide probes in PET after injection into the blood
circulation [2]. In vivo fluorescence imaging is an alternative non-
invasive imaging technique, which can be used separately or in
adjunction with other modalities for timely monitoring of the
biomarker during the course of treatment. This method is simple
and portable.
Recent advances in fluorescent probes, targeting specific disease
biomarkers, have opened a new era in in vivo fluorescence imaging.
They make it a promising tool for medical diagnostics [3–8].
Particularly, development of Near InfraRed (NIR) fluorescent
probes has significantly improved the capability of in vivo
fluorescence imaging, due to low autofluorescence background
and deep penetration of the NIR light in the tissue [9].
Fluorescence imaging can be realized in the form of measuring
the fluorescence intensity distributions and/or the fluorescence
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evaluation of the average time that electronically excited
fluorophore stays in the excited state before its transition to a
ground state, accompanied by photon emission. Fluorescence
lifetime can be measured by time-domain or frequency domain
techniques [19–22]. In this study, we used the more accurate
former method and measured the exponential transient decay of
the fluorescence intensity with time after considering the effect of
the impulse response of the system. It has been shown that
fluorescence lifetime is independent of the concentration of the
fluorophores and the intensity of the excitation light. Fluorescence
lifetime can remain constant even within fivefold fluctuation in the
intensity of the excitation light [23]. On the other hand, it can be
sensitive to local biochemical environment, e.g., temperature and
pH or molecular interactions [24,25]. This property makes the
fluorescence lifetime imaging a promising candidate for detecting
and monitoring specific cancer receptors in the diagnosis and
treatment of diseases. Another important application of this
technique is to investigate the effectiveness of early-phase
treatment response by monitoring the binding of drug molecules
to the tumor cells.
In this study, we targeted the Human Epidermal Growth Factor
2 (HER2/neu) receptor, which is one of the important biomarkers
in many cancers, including breast and ovarian cancer [26].
Overexpression of this receptor is correlated with poor prognosis
and resistance to specific chemotherapies [27]. To optimize the
treatment procedure, it is important to assess the expression of the
HER2 receptor in the diagnostic process and to monitor it in vivo
over the course of treatment. To assess status of this receptor, we
applied a HER2-specific Affibody conjugated to near infrared
(NIR) fluorescent dye.
Though several recent studies have shown improved Signal/
Noise ratio for in vivo fluorescence imaging by caging the
fluorophore dyes using Polymersomes [28], nanotubes [29] or
using nanoparticles [30] as an alternative for a single molecule
fluorophores, Affibody-DyLight750 conjugate, investigated in the
manuscript, seems to be a better suited probe for our goal, i.e.,
characterization of HER2 receptors overexpression in tumors
in vivo.
Affibody molecules [31–34] are very stable proteins. They are
relatively small (8.3 kDa), about 20 times smaller than antibodies.
Like any other small molecules, they can accumulate in the tumor
through the leaky tumor vasculatures. Their major diagnostic
advantage is that they can be made highly specific to particular
cancer cell receptors, for example, HER2. After binding to these
receptors, the unattached probes wash out and mainly bound
fluorescent ligands contribute to the signal from the tumor area at
later times. This significantly improves the contrast of the tumor,
compared to the background.
In our previous study, we have shown that the dynamic changes
in fluorescence intensity levels of HER2-specific Affibody proteins,
conjugated with a fluorescent dye, can be used to quantify the
HER2 expression in tumor cells [35–37]. Relatively fast
pharmacokinetics of the Affibody-DyLight750 conjugate acceler-
ates data collection and simplifies their analysis. The method,
presented in the current manuscript, though less quantitative at
the current stage comparing to pharmacokinetics analysis, allows
one to assess the HER2 status of the tumor from just one time-
resolved measurement. It does not require repeating measure-
ments of the fluorescence from the tumor after the probe injection
that imply much longer times of observation. Suggested approach
can be used for a preliminary assessment of HER2 expression in
tumor. It is complimentary to quantitative characterization of
HER2 receptors, based on pharmacokinetics.
On the other hand, it has been shown in our earlier studies [35]
that the HER2 Affibody binds to a different epitope of the HER2
receptor than the epitope, targeted by such widely used
monoclonal antibodies as trastuzumab or pertuzumab. This
enables monitoring of HER2 expression during the therapy
without interference with the potential effect of these drugs [35].
In this study, we investigated in live animals whether binding
the Affibody-conjugated fluorescent probe to the HER2 receptor
can influence fluorescence lifetime of the probe. For this purpose,
the fluorescence lifetime were studied in three different cases:
HER2-specific Affibody (His6-ZHER2:GS-Cys) fluorescent probe
in human tumor models with high HER2 expression, HER2-
specific Affibody fluorescent probe in a human tumor model with
no HER2 expression, and HER2-nonspecific Affibody (His6-
ZTaq:GS-Cys) fluorescent probe in human tumor models with high
HER2 expression, all in the mouse model in vivo. The results reveal
significant differences in the fluorescence lifetimes between the
tumor area and the contralateral site, when and only when, the
binding of optical probe to the tumor receptors could occur. To
the contrary, no change in fluorescence lifetime was observed in
the cases where the optical probes have no affinity to the HER2
receptors.
Materials and Methods
Contrast Agent
In these experiments, two different AffibodyH molecules (Affi-
body, Stockholm, Sweden) were used: HER2-specific Affibody
(His6-ZHER2:GS-Cys) and HER2-nonspecific Affibody (His6-
ZTaq:GS-Cys), both conjugated with the Dylight750 fluorescent
probe (Thermo-Fisher-Scientific,Waltham, Massachusetts). Dy-
light750 is bright enough to be used for in vivo studies without
any modification and can easily be conjugated to the HER2
specific/non-specific Affibodies. The conjugation ratio of Dy-
light750 to affibody protein is 1:1.
We measured the lifetime of Affibody probe in chemical buffers
(with a composition of citric acid, boric acid, and mono-sodium
phosphate ranging from a pH of 4.5 to 9. No significant change in
the fluorescence lifetime was observed over the whole range of pH
(Fig. 1A). Sterilized saline solution was used for 3 times dilution of
the Affibody probe before injection.
We also measured the fluorescence lifetime of Affibody probe in
chemical buffer with pH of 6.86 by increasing its BSA
concentration from 0% to 5% (Bovine Serum Albumin, Fraction
V, Minimum 96%, Sigma Co.). The lifetime of the Affibody probe
proved to be sensitive to the presence of BSA proteins (Fig. 1 B).
We have not observed a decrease in the fluorescence lifetime
relative to the Affibody probe, used for injection.
Cell culture
For animal studies, three human tumor xenograft models
expressing different levels of HER2 were used in this study. BT-
474 and NCI-N87 are human tumor cell lines with a high level of
HER2 (HER2/neu) expression: 243624 ng/mg and
395641 ng/mg protein, respectively, while MDA-MB-468 is a
human tumor cell line with no HER2 expression. All three cell
lines were obtained from American Type Culture Collection
(ATCC; Manassas, VA). For in-vitro study, we have used either
SK-BR-3 cell line with high level of HER2 expression or HER2-
negative MDA-MB-468 human cancer cell line. SK-BR-3 has
been chosen among HER2 positive cell lines because of its better
attachment to the plate. The cells were grown in RPMI (BT-474,
NCI-N87), DMEM-F12 (SK-BR-3, MDA-MB-468) culture media
supplemented with 10% fetal bovine serum (FBS) and Pen/Strep
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humidified incubator. Solution of 0.05% trypsin and 0.02%
EDTA was used for cells detachment.
In vitro study
HER2-positive SK-BR-3 and HER2 negative MDA-MB-468
cells were placed on 8-chambered confocal slides and incubated
overnight. After 24 hours incubation, Affibody-DyLight488-con-
jugate was added to cells media at 0.5 mg/ml concentration. After
additional 30 min incubation at 37uC, 2 mg/ml of Hoechst 33342
(Invitrogen, Carlsbad, CA) were added to the cells and incubated
for another 1 hour for nuclei staining. Then cells were washed
three times and imaged in PBS by Zeiss LSM 510 confocal
microscope (further details of the experiment will be presented
elsewhere [in preparation]). We have used marker similar to
Affibody-DyLight750-conjugate (Affibody-DyLight488), because
Zeiss LSM 510 confocal microscope does not operate at the near
infrared wavelengths.
Additionally, to confirm the consistency of obtained results with
Affibody-DyLight750-conjugate and evaluate the lifetime of the
Affibody probe in vitro, FLIM microcopy of the cell cultures was
performed by a specially adapted Olympus FV1000 inverted laser-
scanning two-photon microscope [38] for imaging through non-
descanned detection pathway in one-photon mode. Even though,
these modifications reduced the microscope depth resolution
significantly compared to confocal microscopy, it allowed to
demonstrate clearly binding of HER2-Affibody-DyLight750-
conjugate to the outer membrane of HER2 positive SK-BR-3
cells.
Briefly, for imaging, an Olympus Fluoview 1000 galvo-mirror
laser scanning microscope equipped with a wide-band tunable
‘‘Mai Tai DeepSee’’ Ti-Sapphire laser (by Newport Spectra-
Physics) was used. The laser was set to a one-photon excitation
wavelength of 717 nm (to minimize the scattering by dichroic
mirror). Substantial laser attenuation with a combination of
orthogonal calcite polarizer and a metallic neutral density filter
was used to avoid detector saturation and sample photobleaching.
Sample was mounted on an inverted stage in an 8-well plate and
illuminated with a long-pass 740–830 nm dichroic mirror (FF741-
Di01 by Semrock) by means of a water-immersion 0.8 NA
LUMPlanFl N 406 objective from Olympus. Two stacked
Newport Oriel 51350 color glass 780 nm longpass filters were
used in front of a red-sensitive Peltier-cooled fast-rise PMT module
(Becker & Hickl model PMC-100-20) to eliminate scattering,
second harmonic generation and cells autofluorescence. Since the
detector was mounted on a non-descanned side port without any
special filtering, effectively Z-resolution was decreased significantly
in favor of collection efficiency. A fast-response silicon photodiode
(Becker & Hickl model PHD-400-N-12) was used for laser
synchronization. Photon counting events were discriminated,
registered and assigned to pixel locations by Becker&Hickl SPC-
830 PCI board. Data analysis was performed with SPCImage ver.
3.2 software by Becker&Hickl. Typical photon accumulation times
varied from 60 to 300 s employing fast bidirectional scanning
mode to further reduce photobleaching. Average count rate was
kept well under 2 MHz to avoid pulses pileup.
The instrument response function, generated from crushed urea
crystals in oil, was detected as second harmonic generation (laser
tuned to 820 nm) through a proper set of dichroic/emission filters
and measured as FWHM ,190 ps (in our case was determined by
the PMT transit time spread).
Animal Preparation
For animal studies, the cultured cancer cells were implanted
into the right forelimb of xenograft female nude mice. Five million
cells were injected in 0.1 mL of 50% Matrigel into the right
forelimb. The study was approved by National Institutes of Health
Animal Care and Use Committee (Approval ID: ROB117). After
the tumors grew to the size of 0.5–1 cm, mice were transferred to
our imaging facilities. Before imaging, the mouse was anesthetized
by isoflurane inhalation. The mouse was placed on a temperature-
controlled stage and two sets of images from the tumor region and
contralateral site were captured before injection. Then, 10 mgo f
the Affibody conjugated to fluorescent probe was injected through
the tail vein. Images were captured continuously every 30 min for
the first 5 hours. Tumor tissue was extracted from animals
24 hours post HER2-Affibody-DyLight750 injection, fixed in 10%
neutral burred formalin (NBF) (Sigma-Aldrich, St. Louis, MO).
Tumors were stained for HER2 expression (Herceptest, Daco) and
Affibody distribution pattern.
It should be noted that Affibody-DyLight compounds do not
induce toxic effects on breast cancer cells, as was demonstrated by
Figure 1. Effect of (A) pH and (B) BSA concentration on the lifetime of DyLight750 conjugated to HER2 specific Affibody probe.
doi:10.1371/journal.pone.0031881.g001
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presented elsewhere [in preparation]). To further validate the low
toxicity of the probe in vivo, we kept several mice with the injected
doses as high as 0.5 mg/kg alive up to 1 month after injection of
the Affibody-DyLight750 compound without observing any
toxicity effects in the mouse.
In-vivo Lifetime Imaging System
The in-vivo lifetime imaging system consisted of a tunable pulse
laser with a pulse width of 100 fs and repetition rate of 80 MHz.
The laser was tuned to an excitation wavelength of 750 nm. The
light pulses scanned the target (tumor or contralateral site) of an
animal in a raster pattern through a scanning head with source
and detector fibers in 2 mm distance. The animal was placed
within a dark chamber on a temperature-controlled scanning
stage. The reflected fluorescence signal was filtered by a 780 nm
long-pass emission filter. The detected photons were captured by a
photomultiplier tube (PMT) and photons were counted by a time-
correlated single-photon counter (TCSPC). Initialization, scan-
ning, and acquisition were controlled by the Labview software.
The details of the imaging system can be found in [15]. The
fluorescence lifetime was estimated from a curve fitting of the data
to a single exponential decay function, optimized by iterative
reconvolution of single decaying exponential with the impulse
response function of the system. We truncated the tail of the time-
resolved intensity data due to its more susceptibility to photon
transport path variations. In our preclinical studies, since the
tumor is located in mouse forelimb subcutaneously, the depth of
the tumor does not have a significant effect on the lifetime,
however, for applications dealing with the deeply embedded
tumors, the effect of the photon diffusion on the observed time-
resolved fluorescence intensities should be taken into account.
Results
In vivo Study
To investigate the effect of binding the HER2-specific Affibody
fluorescent probe to the HER2 receptor-positive tumor on
fluorescence lifetime, three different cases were considered. In
the first case, the HER2-specific Affibody (His6-ZHER2:GS-Cys)
optical probe was injected in mice with high HER2-expressing
human tumor carcinomas. In the second case, a HER2-
nonspecific Affibody (His6-ZTaq:GS-Cys) fluorescent probe was
injected in mice with the same HER2-expressing human tumor
carcinomas as in the first case, and in the third case, the HER2
specific Affibody (His6-ZHER2:GS-Cys) fluorescent probe was
injected in mice with no HER2-expressing tumor.
In the first experiment, HER2-specific Affibody was injected
into four mice with a high level (+3) HER2-expressing human
tumor carcinoma, BT-474. Fig. 2 shows the results of in vivo
measurements of fluorescence intensity and lifetime at the tumor
area and the contralateral site. Fig. 2C shows the difference
between the fluorescence intensity at the tumor (Fig. 2A) and the
contralateral sites (Fig. 2B) 1 hour after injection, mapped on the
tumor area. Fig. 2D shows the dynamics of the maximum
fluorescence intensity at the tumor region and contralateral site for
6 hours after the injection. The pixel with maximum intensity was
used to characterize the tumor. The fluorescence mapping at the
contralateral site was averaged over 16 pixels since there was no
specific point to target at the contralateral site. Averaging over 16
pixels has been used for noise reduction. To demonstrate the
variations of the lifetime and fluorescence intensity throughout the
scanned area we presented maps of fluorescence intensity and
lifetime at the contralateral and tumor regions. The data shown in
the Fig. 2D and Fig. 2H are the average values of the
measurements over 4 mice (Markers show the average and bars
show the standard deviation). Fig. 2G shows the difference
between the fluorescence lifetime at the tumor (Fig. 2E) and
contralateral sites (Fig. 2F) 1 hour after injection, mapped on the
tumor region. The fluorescence lifetime in the tumor area and
contralateral site for over 6 hours after injection is shown in
Fig. 2H. In Figs. 2H, the data, corresponding to the pixel with
maximum intensity were used for lifetime calculations since it had
the highest signal to noise ratio.
In all experiments, the data were captured from the tumor and
contralateral sites at the same time range as the first experiment.
For the fluorescence intensity and lifetime maps, we chose the
measurement data at 1 hour after injection, corresponding to a
case, when considerable amount of fluorescent dyes were available
in both contralateral and tumor sites.
As an example, the fitting curves obtained by SPCImage
software, (ver. 3.2, Becker & Hickl GmbH) are shown in Fig. 3 for
measurements both at the tumor (Fig. 3A) and contralateral
(Fig. 3B) sites. These data are measurements, performed 1 hour
after injection the HER2-specific Affibody, conjugated to Dy-
Light750, in mouse with human tumor carcinoma xenograft (BT-
474). This cell line is known to have high expression of HER2.
Blue and green graphs show the measurement data and the
impulse response function of the system, respectively. The fitting
was based on single exponential decay model. Parameter a1 shows
the relative of amplitude of the signal used in single exponential
decay model and t1 is the lifetime (in picoseconds). The small
graph at the bottom is the fitting error and the red line presents the
fitted curve.
In the second experiment, we have used three mice with the
same HER2 positive carcinoma (BT-474). Contrary to the
previous experiment, an HER2-nonspecific Affibody (His6-
ZTaq:GS-Cys) optical probe was used as a contrast agent. The
results are shown in Fig. 4. Due to non-specificity of ZTaq affibody
to HER2 receptors, no probe binding/accumulation in HER2
positive tumors was observed in this experiment.
For the third experiment, three mice with the HER2-negative
model (MDA-MB-468) were used for the study. Again the HER2-
specific Affibody (His6-ZHER2:GS-Cys) optical probe was used as a
fluorescent contrast agent. In this specific human tumor model, due
to the lack of the HER2 receptors in the tumor area, HER2
Affibody did not bind to the tumor cells. The intensity at both
tumor and contralateral site decreased significantly in 2–3 hours
afterinjection(Fig.5D).Thefluorescencelifetimewasalsoobserved
to be the same at both tumor and contralateral sites (Fig. 5H).
The same tests were repeated for the NCI-N87 tumor model.
NCI-N87 cells are also known to have a high level of HER2
expression [26]. The fluorescence intensity and lifetime were
measured in vivo after injection of fluorescent probe, based either
on HER2-specific Affibody (His6-ZHER2:GS-Cys) or HER2-
nonspecific Affibody (His6-ZTaq:GS-Cys). The results are shown
in Fig. 6 and Fig. 7, respectively.
Before injection, the fluorescence lifetime of Dylight750,
conjugated to HER2-specific Affibody (His6-ZHER2:GS-Cys), was
measured as 0.71 ns. However, the lifetime of Dylight750
conjugated to HER2-nonspecific Affibody (His6-ZTaq:GS-Cys)
was measured as 0.62 ns. This lifetime difference between HER2-
specific and non-specific were consistence in our in-vivo
measurements at contralateral site.
To evaluate potential contribution of the autofluorescence into
the measured fluorescence intensities, we have measured signal
before the probe injection both at the tumor and contralateral
sites. Figs. 8A–8B show intensity map of the 16 pixels at the tumor
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probe. A comparison between the autofluorescence (before
injection) and the fluorescence signal after injection of (A) HER2
specific Affibody-Dylight750 (B) HER2 non-specific Affibody-
Dylight750 in mice with NCI-N87 tumor xenografts is presented
in Figs. 8C–8D for the tumor and the contralateral sites,
respectively. These measurements confirm that the autofluores-
cence level is very low relative to the probe fluorescence signal,
Figure 2. In vivo fluorescence imaging of xenograft mouse with high HER2 expressing human tumor model (BT-474) after injection
of HER2-specific AffibodyH (His6-ZHER2:GS-Cys) conjugated to Dylight750. (A) Fluorescence intensity map at the tumor region.
(B) Fluorescence intensity map at the contralateral site (C) The difference of fluorescence intensity at the tumor region and the contralateral site,
mapped on the tumor region. (D) Pharmacokinetics of the fluorescence intensity at the tumor region and contralateral site after the injection over
time. The fluorescent intensity was averaged over 16 pixels at the contralateral site. The data in Figs. (D) and (H) are the average data of four mice.
Markers show the average and bars show the standard deviation. (E) Fluorescence lifetime map at the tumor region. (F) Fluorescence lifetime map at
the contralateral site. (G) The difference of fluorescence lifetime at the tumor and the contralateral site mapped on the tumor region.
(E) Pharmacokinetics of the fluorescent lifetime at the tumor region and contralateral site after injection over time. All lifetime and fluorescence
intensity maps in figures 2,4–7 are from measurements at 1 hour after the injection of Affibody probe. In all measurements, the photons were counted
over two seconds integration time, t0. To exclude saturation effect of the 16 bit camera, in the brightest pixels, where the corresponding limit of 65536
counts was reached before time t0, we have renormalized the data by multiplying photon counts, measured for lower integration time t, by factor t0/t.
doi:10.1371/journal.pone.0031881.g002
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In prescans (before probe injection), we were not able to
distinguish the tumor region from the contralateral site (since the
autofluorescence was lower than the noise floor of our system,
lifetime estimates prove to be impossible in this case).
The histological images of extracted tumor tissues 24 hours
after injection for tumor with no HER2 expression (9A–9B) MDA-
MB-468, and tumors with high HER2 expression (9C–9D) BT-
474 and (9E–9F) NCI-N87 are provided in Fig. 9.
To be more quantitative in the assessment of HER2 expression
in the tumors we have also performed ELISA assays of the ex vivo
tumor tissue, extracted 24 hours after initial in vivo fluorescence
imaging. According to ELISA readings, the HER2 expression in
HER2-negative tumor (MDA-MB-468) was negligible
(0.9260.17 ng/mg protein). To the contrary, in HER2-positive
(3+) tumors BT-474, and NCI-N87, the measured HER2
expression was much higher, i.e., 243624 ng/mg and
395641 ng/mg, respectively.
In vitro studies
To understand the mechanism involved in the change in
lifetime, we also tested the affinity and specificity of our probe to
HER2 receptors in vitro, using cell cultures. It was shown by
confocal microscopy that cancer cells, expressing high level of
HER2 receptors, have evident membrane accumulation of the
fluorescence dye after exposure to HER2-Affibody-Dylight488-
conjugate. Neither membrane retention nor intracellular uptake of
the probe was observed for HER2-negative MDA-MB-468 cells
even after 24-hours of continuous exposure to HER2 targeting
probe (Fig. 10).
For in vitro imaging with modified FLIM microscope, we have
also observed the binding of the HER2-Affibody-Dylight750
probes to the HER2 positive (3+) SK-BR-3 cells’ outer membranes
(Fig. 11D).
To elucidate the mechanism of lifetime changes due to Affibody
binding to HER2 receptors, we imaged the cells within PBS and
cell culture media with 10% FBS (the cells did not survive in 5%
BSA solved in PBS). The data processing was performed with
SPCimage software.
Figures 11A–11C and 11D–11F present the results on SK-BR-3
cell cultures in PBS and in cell culture media, containing 10% of
FBS, respectively. Fluorescence intensity maps for both cases are
shown in Figures 11A and 11D, while Figure 11B and 11E present
corresponding fluorescence lifetime maps. The histograms in
Figs. 11C and Fig. 11F illustrate observed distributions of the
fluorescencelifetimeforHER2-Affibodyprobemolecules,boundto
SK-BR-3 cancer cells, for two considered types of cell media. The
results reveal similar peak values and distribution for both cases.
The lifetimes of the dye in PBS, obtained with our FLIM system
prove to be practically equal (712 ps). They are very close to what
we have obtained for HER2 specific Affibody probe with our in
vivo system before injection (,710 ps).
Figure 3. An example of fitting results obtained by SPCImage software, (ver. 3.2, Becker & Hickl GmbH) for measurements at the
tumor (A) and contralateral (B) sites, 1 hour after injection of HER2-specific Affibody conjugated to Dylight750 in a mouse with
high HER2 expressing human tumor model (BT-474). X axis is the amplitude and y axis is the measurement time (ns). Blue and green graphs
show the measurement data and impulse response function of the system, respectively. The fitting was based on single exponential decay model.
Parameter a1 shows the relative of amplitude in single exponential decay model and t1 is the lifetime (in picoseconds). The small graph at the bottom
is the fitting error and the red line shows the fitted curve.
doi:10.1371/journal.pone.0031881.g003
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This paper is focused on the effects of probe binding to cell
receptors in in vivo system (mouse model of human cancer). We
have studied three different scenarios, HER2 specific Affibody in
tumor with no HER2 expression, HER2 specific Affibody in
tumor with high HER2 expression and HER2 non-specific
Affibody in tumor with high HER2 expression.
In human tumor models with high HER2 expression (Figs. 2
and 6), we observed a very high degree of accumulation of HER2-
specific fluorescent dyes in the tumor volume for more than
24 hours after injection. In the same animals, the fluorescent
Figure 4. In vivo fluorescence imaging of xenograft mouse with high HER2 expressing human tumor model (BT-474) after injection
of HER2-nonspecific AffibodyH (His6-ZTaq:GS-Cys) conjugated to Dylight750. (A) Fluorescence intensity map at the tumor region.
(B) Fluorescence intensity map at the contralateral site (C) The difference of fluorescence intensity at the tumor region and the contralateral site,
mapped on the tumor region. (D) Pharmacokinetics of the fluorescence intensity at the tumor region and contralateral site after the injection over
time. The data in Figs. (D) and (H) are the average data of three mice. Markers show the average and bars show the standard deviation. (E rpar;
Fluorescence lifetime map at the tumor region. (F) Fluorescence lifetime map at the contralateral site. (G) The difference of fluorescent lifetime at the
tumor region and the contralateral site mapped on the tumor region. (E) Pharmacokinetics of the fluorescent lifetime at the tumor region and
contralateral site after injection over time.
doi:10.1371/journal.pone.0031881.g004
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fluorescence intensity decreased exponentially with the decay time
,1 hour. The fluorescence lifetime of the Affibody-Dylight750
conjugate at the contralateral site is close to that of before
injection. To the contrary, the measured fluorescence lifetime was
decreased significantly (,100 ps) in the tumor area presumably
because of binding to the tumor HER2 receptors.
In the second case (Figs. 4 and 7), His6-ZTaq:GS-Cys could not
bind to HER2 receptors; therefore, the fluorophore probes were
washed out from tumor as well, and the intensity was decreased in
Figure 5. In vivo fluorescence imaging of xenograft mouse with no HER2 expressing human tumor model (MDA-MB-468) after
injection of the HER2-specific AffibodyH (His6-ZHER2:GS-Cys) conjugated to Dylight750. (A) Fluorescence intensity map at the tumor
region. (B) Fluorescence intensity map at the contralateral site. (C) The difference of fluorescence intensity at the tumor region and the contralateral
site, mapped on the tumor region. (D) Pharmacokinetics of the fluorescence intensity at the tumor region and contralateral site after the injection
over time. The data in Figs. (D) and (H) are the average data of three mice. Markers show the average and bars show the standard deviation.
(E) Fluorescence lifetime map at the tumor region. (F) Fluorescence lifetime map at the contralateral site. (G) The difference of fluorescent lifetime at
the tumor and the contralateral site mapped on the tumor region. (E) Pharmacokinetics of the fluorescent lifetime at the tumor region and
contralateral site after injection over time.
doi:10.1371/journal.pone.0031881.g005
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also show negligible difference between the fluorescence lifetime at
the tumor and contralateral regions.
In the tumor model with no HER2 receptor expression (Fig. 5),
the HER2-specific Affibody could not bind to the tumor cells.
Therefore, the intensity at both tumor and contralateral sites
decreased significantly in 2–3 hours after injection due to washout
(Fig. 5C). The fluorescence lifetime was also observed to be the
same at both the tumor and contralateral sites.
Statistical analysis substantiated these conclusions about qual-
itative differences between binding and no binding cases (see
below).
Figure 6. In vivo fluorescence imaging of xenograft mouse with high HER2-expressing human tumor model (NCI-N87) after injection
of the HER2 specific AffibodyH (His6-ZHER2:GS-Cys) conjugated to Dylight750. (A) Fluorescence intensity map at the tumor region.
(B) Fluorescence intensity map at the contralateral site. (C) The difference of fluorescence intensity at the tumor region and the contralateral site,
mapped on the tumor region. (D) Pharmacokinetics of the fluorescence intensity at the tumor region and contralateral site after the injection over
time. The data in Figs. (D) and (H) are the average data of three mice. Markers show the average and bars show the standard deviation.
(E) Fluorescence lifetime map at the tumor region. (F) Fluorescence lifetime map at the contralateral site. (G) The difference of fluorescent lifetime at
the tumor and the contralateral site mapped on the tumor region. (E) Pharmacokinetics of the fluorescent lifetime at the tumor region and
contralateral site after injection over time.
doi:10.1371/journal.pone.0031881.g006
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reproduce the lifetime ‘‘binding’’ effect in cell cultures, probably
because it is not simply binding to HER2 receptors per se that
results in smaller lifetimes, but a combination of several processes,
for example, involving the intermediate binding of the probe to
blood albumin in circulation [39] with subsequent dissociation of
specific probe inside the tumor from blood albumin through
binding to HER2 receptors. For this reason, we believe that failure
to reproduce ‘‘binding’’ effect in vitro up to now, have not put in
doubt our in vivo findings; in vivo experiments were done with
several independent controls: tumor region versus contralateral
site, HER2-positive versus HER2-negative tumors, HER2-specific
Figure 7. In vivo fluorescence imaging of xenograft mouse with high HER2 expressing human tumor model (NCI-N87) after injection
of the HER2-nonspecific AffibodyH (His6-ZTaq:GS-Cys) conjugated to Dylight750. (A) Fluorescence intensity map at the tumor region.
(B) Fluorescence intensity map at the contralateral site (C) The difference of fluorescence intensity at the tumor region and the contralateral site,
mapped on the tumor region. (D) Pharmacokinetics of the fluorescence intensity at the tumor region and contralateral site after the injection over
time. The data in Figs. (D) and (H) are the average data of three mice. Markers show the average and bars show the standard deviation.
(E) Fluorescence lifetime map at the tumor region. (F) Fluorescence lifetime map at the contralateral site. (G) The difference of fluorescent lifetime at
the tumor and the contralateral site mapped on the tumor region. (E) Pharmacokinetics of the fluorescent lifetime at the tumor region and
contralateral site after injection over time.
doi:10.1371/journal.pone.0031881.g007
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consistent. Our future in vitro studies will be focused on discovering
the reasons for observed discrepancy between the live mouse and
cell culture fluorescence data. Adequate mimicking of the cancer
tumor microenvironment in vitro is very complicated and likely
would require much more sophisticated setup.
The main difference between the three in-vivo study cases was
the binding of HER2 Affibody to the HER2 receptors in the
tumor. The other factors, like penetration of the fluorescence dye
in the tumor area due to the leakiness of the tumor, the pH
difference in the tumor and blood protein concentration should be
the same in the case of same-type HER2-positive tumors, assessed
with specific or non-specific Affibodies. On the other hand, for
different tumor types, one could expect some differences in
tumors’ vascularity/leakiness, pH, blood protein etc. Thus,
observed close similarity between the fluorescence lifetimes from
tumor areas in the cases of HER2 positive tumors, imaged with
non-specific probe, and HER2 negative tumors, imaged with
similar, but HER2 specific probes (see Figs. 4, 7 and 6), further
emphasizes the importance of the probe binding to HER2
receptors for fluorescence lifetime to decrease, indicating that all
other mentioned above factors play relatively minor role. It should
be also noted that in cases, not involving specific HER2 binding,
fluorescence lifetime behaves similarly at the tumor and
contralateral sites. We have shown that even at early times after
injection, the fluorescence lifetime at the tumor is shorter in all
cases, when we expect Affibody binding to the HER2 receptors,
relative to other two control cases, or the contralateral site. Thus,
our analysis of the observed differences between three studied
cases indicates the major role of the binding of Affibodies to HER2
receptors. We have observed that wherever HER2 binding occurs
(HER2 positive tumor + HER2 specific probe) fluorescence
lifetimes at the tumor, ttum, are shorter by more than 10%,
comparing to that of the contralateral site, tcs. In addition, the
temporal behavior of ttum(t) differs qualitatively from tcs(t), i.e.,
observed lifetimes at the tumor are practically constant ttum&0:62
ns up to time t,5 hours post injection after a small initial drop
(,0.02 ns) during initial t,0.5 hours, while tcs slowly increases
from ,0.7 ns to ,0.75 ns after probe injection (see part H in
Figs. 2,4–7).
In the opposite case (control experiments), when no HER2
binding of the probe can happen, either because the tumors are
HER2 negative, or the tumors are HER2 positive (of the same
types, as analyzed before), but the probe is HER2 non-specific (i.e.,
Figure 8. Comparison of autofluorescence intensity at the tumor and contralateral sites. The autofluorescence intensity map at the (A)
tumor and (B) contralateral sites before injection. Comparison of the autofluorescence intensity before injection and the fluorescence signal after
injection of (C) HER2 specific Affibody-Dylight750 and (D) HER2 non-specific Affibody-Dylight750 in 3 mice with HER2 positive tumor (NCI-N87 tumor
carcinoma) at the tumor and contralateral sites .
doi:10.1371/journal.pone.0031881.g008
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dependencies ttum(t) and tcs(t) are very close (see part H in
Figs. 4, 5 and 7).
It should be noted that intensity changes with time in the
control experiments are similar in both tumor and the contralat-
eral site, presenting exponential decay likely due to probe washout
from the circulation with close characteristic times (part D in
Figs. 4,5 and 7). For HER2 positive tumors, being imaged with
HER2 specific probe, fluorescence intensity grows quickly during
initial 2–3 hours after injection due to probe accumulation/
binding to HER2 receptors and then decreases slowly due to probe
unbinding (part D in Figs. 2 and 6).
The IHC results (Fig. 9) also indicate no expression of HER2
receptors (9A) and no accumulation of HER2-specific Affibody
(9B) in MDA-MB-468 tumor. On the other hand, figures 9C-9F
reveal high overexpression of HER2 in tumors of BT-474 and
NCI-N87 types (3+ tumors according to conventional definition)
and accumulation of HER2 Affibody at the surface of the cancer
cells in these tumors. The quantitative values for HER2 expression
in tumors, obtained by ELISA assays also confirm the IHC results.
Table 1 demonstrates statistical significance of the ‘‘binding’’
effect. We have used Wilcox Two-Sample U-test – Software R
[40], to compare the tumor and contralateral site values of
lifetime. The p-values were calculated based on the mean values of
the measurement data at the tumor and contralateral site for three
mice in each study. We combined the data in each subsample,
because the lifetime data for three mice were very similar, as
shown in Figs. 2, 4–7, part H. The p-value was calculated by
comparing the measurements of the tumor and contralateral site
in the range between 30 min to 5 hours after injection.
The results show that in those cases, when HER2 binding can
occur, there is a significant statistical difference between two time
sequences of lifetime measurements, corresponding to the tumor
and contralateral site (p-values,6e-4), while in the case of no
probe binding the null hypothesis that both sequences are
statistically similar holds (p-values.0.74). To our mind, these
observations provide strong evidence that binding of the
fluorescent ligands to receptors results in the noticeable reduction
in the fluorescence lifetimes.
Summary
In this study, we observed that the fluorescence lifetime of
HER2 targeting optical probe changes after binding to HER2
receptors in the tumor area. The fluorescence lifetime is not
sensitive to the intensity of excitation light and concentration of
fluorophores, and this is one of the main advantages of
fluorescence lifetime over fluorescence intensity measurements.
The results show that comparison of the fluorescence intensity,
originating from the tumor, with that of the contralateral site alone
is not a good indicator of binding the fluorescent probe to the
HER2 receptors. In the cases, when the Affibody did not bind to
the HER2 receptors (e.g., Figs. 4B and 5B); there is an intensity
contrast in the tumor are, relative to the contralateral site,
probably due to the leakiness of tumor vascularization. To observe
the binding of a fluorescent probe to a specific tumor receptor,
determining the dynamic of the intensity contrast between tumor
and contralateral site is required. This process involves imaging of
the tumor for several hours after a probe injection. From practical
point of view, the latter requirement may cause limitations for the
clinical studies. On the other hand, the results of this study show
that the difference between the fluorescence lifetime at the tumor
and contralateral site is almost constant over time, and a relatively
small time window would be sufficient to indicate the HER2
overexpression, making the technique more patient-friendly.
Figure 9. Histological (IHC) images of tumor tissues for tumor with no HER2 expression (A–B) MDA-MB-468, and highly expressed
HER2 tumor (C–D) BT-474 and (E–F) NCI-N87. Tumor tissue was extracted from animals 24 hours post HER2-Affibody-DyLight750 injection,
fixed in 10%NBF and analyzed by IHC for detection of HER2 status (A,C and E) and Affibody presence (B,D and F).
doi:10.1371/journal.pone.0031881.g009
Figure 10. Confocal microscopy of HER2 positive (A) and
negative (B) cells exposed to HER2-Affibody-DyLight488. Blue
color shows the cell nuclei labeled with Hoechst 33342 and green color
shows the HER2-Affibody-DyLight 488.
doi:10.1371/journal.pone.0031881.g010
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PLoS ONE | www.plosone.org 12 February 2012 | Volume 7 | Issue 2 | e31881These results can help to create a new paradigm in the ‘‘image
and treat’’ concept to assess the presence of specific cancer
biomarkers and to monitor the influence of the drug on the tumor
cells in vivo, especially in the early stage of the therapy. Application
of time-resolved fluorescence imaging can reveal binding of
specific optical probes to targeted tumor receptors in vivo.I n
addition to the clinical applications, this method can also be
considered as a potential laboratory tool in pre-clinical animal
studies and pharmaceutical research.
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